Piper Jaffray analyst Steven Breazzano remains sidelined, but optimistic on Clovis Oncology Inc (NASDAQ:CLVS) following the firm’s conference call discussing FDA approval of …
Clovis Oncology Inc (NASDAQ:CLVS) shares are under pressure today after the biotech firm presented additional detailed efficacy and safety data from the NDA dataset of …
We await full ruca data at ESMO to better define rucaparib’s profile, says Piper Jaffray
